| |
|
|
| |
| 投稿时间： 2015-08-14 最后修改时间： 2015-10-03 摘要点击次数: 3030 全文下载次数: |
| |
| 引用本文：伍琳, 陈永法.韩国和德国专利药价格谈判模式比较研究及启示[J].中国卫生政策研究,2015,8(10):62-67 |
|
| 伍琳, 陈永法 |
| 中国药科大学 江苏南京 211198 |
| 基金项目:华海药业研究生创新基金(CX14S-015HH) |
| |
|
| | 摘要:为完善我国专利药价格谈判制度,本文从目标、程序及效果三方面,比较分析韩国和德国专利药价格谈判模式的共性与特点,从而为中国提供借鉴。结果发现,韩国和德国专利药价格谈判均以提高国家医保基金使用效率为关键目标,并通过科学的职责分工确保谈判的公平与效率,但技术评估标准的选择因国情差异而存在较大不同。建议我国加强专利药价格谈判与医保报销政策的衔接,建立以专利药创新程度为核心的评估标准体系,同时应制定科学合理的谈判程序与职责分工。 | |
|
|
关键词:专利药 价格谈判 药品报销 技术评估
|
| |
| Comparative analysis on price negotiation models of patented drugs in Korea and Germany and its implications for China |
| WU Lin, CHEN Yong-fa |
| China Pharmaceutical University, Nanjing Jiangsu 211198, China |
| |
|
| | Abstract:Objective: To provide policy recommendations for improving price negotiation system of patented drugs in China. Methods: This paper comparatively analyzes the commonalities and characteristics between Korea' and Germany's price negotiation models for patented drugs from three aspects of their goals, procedures and effects. Results: The key objective of both Korea' and Germany's price negotiation systems for patented drugs is to efficiently improve the utilization of national health insurance services, and responsibilities are properly assigned among different institutions to ensure the equity and efficiency of negotiations. However, due to the differences in national circumstances, there is a big difference in the selection of technical assessment criteria. Conclusion: This paper suggests China to strengthen the convergence between price negotiations for patented drugs and medical insurance reimbursement policy, to establish a technical assessment system with the innovation extent for patented drugs as its core, and to develop scientific and rational negotiation procedures and division of responsibilities as well. | |
|
|
|
|
